Heterogeneity of the efficacy of the 23-valent pneumococcal polysaccharide vaccine caused by various underlying conditions of chronic pulmonary disease in older patients: prospective cohort study

Heterogeneity of the efficacy of the 23-valent pneumococcal polysaccharide vaccine caused by various underlying conditions of chronic pulmonary disease in older patients: prospective cohort study

Bibliographic Details
Main Authors:	Inoue, Satoshi, Watanuki, Yuji, Kaneko, Tetsuji, Sato, Takashi, Miyazawa, Naoki, Kaneko, Takeshi, Ishigatsubo, Yoshiaki, Morita, Satoshi, Natsumeda, Yutaka, Mizushima, Shunsaku
Format:	Online
Language:	English
Published:	BMJ Group 2011
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3191416/

Similar Items

Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to the 23-valent pneumococcal polysaccharide vaccine in elderly Japanese adults
by: Shiramoto, Masanari, et al.
Published: (2015)

Effect of 23-valent pneumococcal polysaccharide vaccine on medical expenses in Japan
by: Satomura, Kazunari, et al.
Published: (2014)

Effectiveness of 23-valent pneumococcal polysaccharide vaccine on diabetic elderly
by: Kuo, Chia-Sheng, et al.
Published: (2016)

Evidence suggesting that oral corticosteroids increase mortality in stable chronic obstructive pulmonary disease
by: Horita, Nobuyuki, et al.
Published: (2014)

Effect of abatacept on the immunogenicity of 23-valent pneumococcal polysaccharide vaccination (PPSV23) in rheumatoid arthritis patients
by: Migita, Kiyoshi, et al.
Published: (2015)

Long-acting beta-agonists reduce mortality of patients with severe and very severe chronic obstructive pulmonary disease: a propensity score matching study
by: Horita, Nobuyuki, et al.
Published: (2013)

A Randomized Clinical Trial of the Immunogenicity of 7-Valent Pneumococcal Conjugate Vaccine Compared to 23-Valent Polysaccharide Vaccine in Frail, Hospitalized Elderly
by: MacIntyre, C. Raina, et al.
Published: (2014)

In vitro immunogenic and immunostimulatory effects of zwitterionized 23-valent pneumococcal polysaccharide vaccine compared with nonzwitterionized vaccine.
by: Abdulamir, Ahmed Sahib, et al.
Published: (2010)

A case series evaluating the serological response of adult asthma patients to the 23-valent pneumococcal polysaccharide vaccine
by: C. R. Laratta, et al.
Published: (2017-06-01)

Effectiveness, immunogenicity and safety of 23-valent pneumococcal polysaccharide vaccine revaccinations in the elderly: a systematic review
by: Remschmidt, Cornelius, et al.
Published: (2016)

Economic Evaluation of Immunisation Programme of 23-Valent Pneumococcal Polysaccharide Vaccine and the Inclusion of 13-Valent Pneumococcal Conjugate Vaccine in the List for Single-Dose Subsidy to the Elderly in Japan
by: Hoshi, Shu-ling, et al.
Published: (2015)

Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Children Aged 6–18 Years with Immunocompromising Conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
by: Bennett, Nancy M., et al.
Published: (2013)

Immunogenicity, Safety, and Tolerability of 13-Valent Pneumococcal Conjugate Vaccine Followed by 23-Valent Pneumococcal Polysaccharide Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant Aged ≥2 Years: An Open-Label Study
by: Cordonnier, Catherine, et al.
Published: (2015)

Immunogenicity and safety of 23-valent pneumococcal polysaccharide vaccine as a booster dose in 12- to 18-month-old children primed with 3 doses of 7-valent pneumococcal conjugate vaccine
by: Thisyakorn, Usa, et al.
Published: (2014)

A Review of the Impact of Pneumococcal Polysaccharide Conjugate Vaccine (7-valent) on Pneumococcal Meningitis
by: Tin Tin Htar , Myint, et al.
Published: (2013)

Cost-Effectiveness Evaluation of the 10-Valent Pneumococcal Non-typeable Haemophilus influenzae Protein D Conjugate Vaccine and 13-Valent Pneumococcal Vaccine in Japanese Children
by: Shiragami, Makoto, et al.
Published: (2014)

Statins reduce all-cause mortality in chronic obstructive pulmonary disease: a systematic review and meta-analysis of observational studies
by: Horita, Nobuyuki, et al.
Published: (2014)

Cost-Effectiveness Analysis of Universal Vaccination of Adults Aged 60 Years with 23-Valent Pneumococcal Polysaccharide Vaccine versus Current Practice in Brazil
by: de Soárez, Patrícia Coelho, et al.
Published: (2015)

Immunogenicity and Safety of the 13-Valent Pneumococcal Conjugate Vaccine versus the 23-Valent Polysaccharide Vaccine in Unvaccinated HIV-Infected Adults: A Pilot, Prospective Controlled Study
by: Lombardi, Francesca, et al.
Published: (2016)

Invasive Pneumococcal Disease and 7-Valent Pneumococcal Conjugate Vaccine, the Netherlands
by: van Deursen, Anna M.M., et al.
Published: (2012)

13-valent pneumococcal conjugate vaccine in Africa
by: Robert Cohen, et al.
Published: (2017-03-01)

Impacts of the 13-Valent Pneumococcal Conjugate Vaccine in Children
by: Esposito, Susanna, et al.
Published: (2015)

Reply to Farkouh RA et al. Comment on “Cost-Effectiveness Evaluation of the 10-Valent Pneumococcal Non-Typeable Haemophilus Influenzae Protein D Conjugate Vaccine and 13-Valent Pneumococcal Vaccine in Japanese Children”
by: Shiragami, Makoto, et al.
Published: (2015)

Assessment of Health Benefits and Cost-Effectiveness of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccination in Kenyan Children
by: Ayieko, Philip, et al.
Published: (2013)

Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada
by: Earnshaw, Stephanie R, et al.
Published: (2012)

Otitis media in children vaccinated during consecutive 7-valent or 10-valent pneumococcal conjugate vaccination schedules
by: Leach, Amanda Jane, et al.
Published: (2014)

Synchronous lung and gastric cancers successfully treated with carboplatin and pemetrexed: a case report
by: Sato, Takashi, et al.
Published: (2012)

Effect of 10-Valent Pneumococcal Vaccine on Pneumonia among Children, Brazil
by: Afonso, Eliane Terezinha, et al.
Published: (2013)

Impact of the 7-valent pneumococcal conjugate vaccine on the incidence of childhood pneumonia
by: ELEMRAID, M. A., et al.
Published: (2013)

Invasive pneumococcal infection despite 7-valent conjugated vaccine
by: Joye, Sebastien, et al.
Published: (2013)

Seven-Valent Pneumococcal Conjugate Vaccine and Nasopharyngeal Microbiota in Healthy Children
by: Biesbroek, Giske, et al.
Published: (2014)

Effect of 23-Valent Pneumococcal Polysaccharide Vaccine Inoculated During Anti-Cancer Treatment Period in Elderly Lung Cancer Patients on Community-Acquired Pneumonia Hospitalization: A Nationwide Population-Based Cohort Study: Erratum
Published: (2015)

Effect of 23-Valent Pneumococcal Polysaccharide Vaccine Inoculated During Anti-Cancer Treatment Period in Elderly Lung Cancer Patients on Community-Acquired Pneumonia Hospitalization: A Nationwide Population-Based Cohort Study
by: Chiou, Wen-Yen, et al.
Published: (2015)

Has the seven-valent pneumococcal conjugate vaccine had an impact on invasive pneumococcal disease in Western Australia?
by: Giele, C., et al.
Published: (2007)

Decrease in Pneumococcal Co-Colonization following Vaccination with the Seven-Valent Pneumococcal Conjugate Vaccine
by: Valente, Carina, et al.
Published: (2012)

Pneumococcal Antibody Concentrations of Subjects in Communities Fully or Partially Vaccinated with a Seven-Valent Pneumococcal Conjugate Vaccine
by: Ota, Martin O. C., et al.
Published: (2012)

Indirect Effect of 7-Valent Pneumococcal Conjugate Vaccine on Pneumococcal Carriage in Newborns in Rural Gambia: A Randomised Controlled Trial
by: Egere, Uzochukwu, et al.
Published: (2012)

Direct Effect of 10-Valent Conjugate Pneumococcal Vaccination on Pneumococcal Carriage in Children Brazil
by: Andrade, Ana Lucia, et al.
Published: (2014)

Invasive pneumococcal pneumonia caused by 13-valent pneumococcal conjugate vaccine types in children with different schedules
by: Hong-Yi Lee, et al.
Published: (2018-04-01)

Pneumococcal carriage in children and their household contacts six years after introduction of the 13-valent pneumococcal conjugate vaccine in England.
by: Jo Southern, et al.